健之佳医药连锁集团股份有限公司 健之佳医药连锁集团股份有限公司 2024 年限制性股票激励计划实施考核管理办法 健之佳医药连锁集团股份有限公司（以下简称"公司"） 为进一步完善公司法人治 理结构，健全公司的激励约束机制，形成良好均衡的价值分配体系，充分调动员工的积极 性，使其更诚信勤勉地开展工作，以保证公司业绩稳步提升，确保公司发展战略和经营目 标的实现，公司拟持续完善长期激励机制，实施 2024 年限制性股票激励计划（以下简称 "本次限制性股票激励计划"或"本计划"）。 为保证本次限制性股票激励计划的顺利实施，现根据《中华人民共和国公司法》《中 华人民共和国证券法》《上市公司股权激励管理办法》《上海证券交易所股票上市规则》 等有关法律、法规和规范性文件以及《健之佳医药连锁集团股份有限公司章程》《健之佳 医药连锁集团股份有限公司 2024 年限制性股票激励计划（草案）》（以下简称"《2024 年激励计划（草案）》"） 的相关内容，并结合公司的实际情况，特制定本办法。 一、考核目的 进一步完善公司法人治理结构，建立和完善公司激励约束机制，保证公司本次限制性 股票激励计划的顺利实施，并在最大程度上发挥股权激励的作 ...

健之佳医药连锁集团股份有限公司 2024 年限制性股票激励计划激励对象名单 注：本激励计划中部分合计数与各明细数相加之和在尾数上如有差异，系以 上百分比结果四舍五入所致，下同。 二、其他核心人员名单（255 人） | 序号 | 姓名 | 职务 | | --- | --- | --- | | 1 | 赵乔珍 | 核心管理人员 | | 2 | 高华 | 核心管理人员 | | 3 | 马昆莉 | 核心管理人员 | | 4 | 高丽 | 核心管理人员 | | 5 | 张春华 | 核心管理人员 | | 6 | 字正峰 | 核心管理人员 | | 7 | 刘小涤 | 核心管理人员 | | 8 | 李娜 | 核心管理人员 | | 9 | 李梅 | 核心管理人员 | | 10 | 左丽华 | 核心管理人员 | | 11 | 马红芹 | 核心管理人员 | | 12 | 吴小勇 | 核心管理人员 | 1 姓名 职务 拟授予的限 制性股票数 量（股） 占本激励计 划公告日股 本总额的比 例（%） 占本激励 计划授出 股份总数 的比例 （%） 江燕银 副总裁 24,000 0.02% 1.36% 李恒 董事、副总裁、董事会 秘书兼财务 ...

2023 年度 非经营性资金占用及其他关联资金往来的 专项说明 | 索引 | 页码 | | --- | --- | | 专项说明 | 1-2 | | 非经营性资金占用及其他关联资金往来情况汇总表 | 1 | 健之佳医药连锁集团股份有限公司 | 信永中和会计师事务所 北京市东城区朝阳门北大街 联系电话: +86 (010)6554 2288 | | | | --- | --- | --- | | telephone: +86 (010) 6554 2288 | 8 号富华大厦 A 座 9 层 | | | ShineWing | 9/F, Block A, Fu Hua Mansion, | | | No.8, Chaoyangmen Beidajie, | | | | +86 (010) 6554 7190 | Dongcheng District, Beijing, 传真: | | | certified public accountants 100027, P.R.China | | +86 (010) 6554 7190 facsimile: | 关于健之佳医药连锁集团股份有限公司 2023 年度非经营性 ...

Financial Performance - The company's revenue for Q1 2024 was CNY 2,313,981,509.90, representing a 6.79% increase compared to CNY 2,166,874,356.81 in the same period last year[4]. - Net profit attributable to shareholders decreased by 31.51% to CNY 52,259,604.68 from CNY 76,303,944.55 year-on-year[4]. - The net cash flow from operating activities dropped significantly by 69.56% to CNY 101,194,323.06, down from CNY 332,485,173.59 in the previous year[4]. - Total revenue for Q1 2024 decreased by 31.25% to CNY 51,884,935.45 compared to CNY 75,474,057.39 in Q1 2023[15]. - Operating profit fell by 39.64% to CNY 59,991,039.35 from CNY 99,383,033.13 year-over-year[15]. - The company reported a decrease in diluted earnings per share by 30.51% to CNY 0.41 from CNY 0.59 in the same quarter last year[5]. - The weighted average return on equity fell by 1.11 percentage points to 1.81% compared to the previous year[5]. - Basic earnings per share fell by 30.51% to CNY 0.41 from CNY 0.59 in the previous year[18]. - The company reported a net investment loss of CNY 2,373,958.37 in Q1 2024, an improvement from a loss of CNY 3,245.68 in Q1 2023[72]. - The total profit before tax for Q1 2024 was ¥60,494,312.59, down from ¥97,454,720.81 in Q1 2023, reflecting a decrease of 38.0%[73]. Store Expansion and Network - The number of stores increased by 1,071, a growth of 25.55%, bringing the total to 5,236 stores[9]. - The company opened 134 new stores in Q1 2024, following the establishment of 799 stores in 2023[15]. - The company has a total of 5,263 stores at the end of the reporting period, representing a 2.87% increase from the beginning of the year and a 25.55% year-over-year growth compared to Q1 2023[25]. - The company has established a strong presence in Chongqing with nearly 600 stores and in Liaoning with 417 stores, indicating rapid market penetration[25]. - The company is focusing on expanding its store network primarily through self-construction and acquisitions, particularly in Yunnan and Hebei[23]. - The total number of retail stores increased to 4,918, representing a net increase of 141 stores or 2.95% compared to the previous year[27]. - The number of self-built stores reached 799 in 2023, with 134 new stores added in Q1 2024[29]. - The company opened 134 new self-built stores and acquired 14 stores in Q1 2024, resulting in a net increase of 147 stores[25]. Revenue Sources and Business Segments - The proportion of medical insurance settlement income to main business revenue decreased from 48% to 42% year-on-year due to policy changes[6]. - Online business grew by 12.78%, increasing its share of main business revenue by 1.24% compared to the previous year[7]. - The gross profit margin for the period was 34.36%, an increase of 1.75% compared to the same period last year[9]. - The gross margin for the pharmaceutical retail segment was 33.21%, with a revenue contribution of 90.34%[37]. - Sales revenue for traditional Chinese medicine, health food, and medical devices decreased by 17.93%, 23.42%, and 12.52% respectively, reflecting market challenges and policy impacts[42]. - Personal care products and convenience goods saw significant revenue growth of 28.68% and 25.65% respectively, indicating strong consumer demand in these categories[43]. - The sales of private label products increased by 33% year-on-year, accounting for 15.46% of total operating revenue, which helped mitigate the decline in gross margin[44]. - Other business income grew by 41.83% year-on-year, now representing 5.75% of total revenue, highlighting successful promotional activities and resource acquisition[44]. Operational Efficiency and Strategy - The company plans to enhance operational efficiency and product quality while focusing on customer needs and competitive pricing strategies in 2024[10]. - The company aims to enhance operational efficiency and service quality through improved information systems, focusing on digital transformation and supply chain collaboration[57]. - The company is committed to reducing rental costs and enhancing operational efficiency as part of its core marketing strategy[62]. - The focus for 2024 includes strengthening product category planning, enhancing gross margin, and increasing promotional efforts with industrial enterprises[59]. - The company will actively respond to the challenges posed by outpatient management policies and improve customer service to adapt to changing consumer behaviors[58]. Cash Flow and Financial Position - The company's cash and cash equivalents decreased to CNY 780,141,461.26 from CNY 857,928,878.48, a decline of 9.0%[67]. - Accounts receivable increased to CNY 530,212,926.20, up 20.4% from CNY 440,476,301.82 as of December 31, 2023[67]. - Inventory rose to CNY 2,516,076,343.45, an increase of 6.0% from CNY 2,373,564,146.48[67]. - Total assets as of March 31, 2024, amounted to CNY 10,055,746,795.96, compared to CNY 9,948,934,505.31 at the end of 2023, marking a growth of 1.1%[68]. - Total liabilities increased to CNY 7,159,245,615.89 from CNY 7,104,318,260.69, reflecting a rise of 0.8%[69]. - The company's equity attributable to shareholders rose to CNY 2,913,389,807.23, up from CNY 2,861,130,202.55, an increase of 1.8%[69]. Market and Consumer Engagement - The company has established a chronic disease management system with 2.8 million members, a 75% increase year-on-year, enhancing customer engagement and service quality[47]. - The number of specialized pharmacies reached 1,341, accounting for 27.27% of total pharmacies, focusing on chronic disease management and specialized care[47]. - The company conducted over 110 health education and medical consultation events during the reporting period, addressing various health issues[48]. - The company is enhancing its multi-channel service capabilities to meet diverse consumer needs, ensuring a comprehensive health service ecosystem[49]. - The coverage rate of physical stores reached 92.97%, with 14.46% of stores operating 24 hours, enhancing customer engagement and cost control[51].

证券代码：605266 证券简称：健之佳 公告编号：2024-012 健之佳医药连锁集团股份有限公司 一、 说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 2023 年度及 2024 年一 季度的经营情况、及财务状况、经营成果等具体情况与投资者进行互动交流和沟 通，在信息披露允许的范围内就投资者普遍关注的问题进行回答。 二、 说明会召开的时间、地点 （一） 会议召开时间：2024 年 04 月 29 日 上午 10:00-11:00 关于召开 2023 年度暨 2024 年第一季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2024 年 04 月 29 日(星期一) 上午 10:00-11:00 会 议 召 开 地 点 ： 上海证券 交 易 所 上 证 路 演 中 心 （ 网 址 ： http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2024 年 04 月 23 日(星期二) 至 04 月 26 日(星期五 ...

证券代码：605266 证券简称：健之佳 公告编号：2024-011 健之佳医药连锁集团股份有限公司 关于为子公司提供担保的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: 特别风险提示：被担保方四川勤康、重庆勤康最近一期经审计的资产负 债率超过 70%，敬请投资者充分关注担保风险。 近期，公司与交通银行股份有限公司云南省分行（以下简称"交通银行"） 签署了《保证合同》，约定公司为全资子公司连锁药房提供连带责任担保，约定 保证担保的最高额债权为主债权本金余额最高额人民币 5,200 万元（大写：伍仟 贰佰万元整），及利息、违约金、损害赔偿金和实现债权的费用之和。 一、担保情况概述 （一）担保基本情况简介 本次被担保方云南健之佳连锁健康药房有限公司（以下简称"连锁药 房"）、四川勤康健之佳医药有限责任公司（以下简称"四川勤康"）、云南健之佳 重庆勤康药业有限公司（以下简称"重庆勤康"）均为健之佳医药连锁集团股份 有限公司（以下简称"公司"）100%持股的全资子公司。 本次公司担保合计金额为 10,200 ...

Investment Rating - The report initiates coverage with a "Buy" rating for the company [2][3]. Core Views - The company is expected to leverage its scale advantages, successful integration experience, and diversified business operations to implement a national dual-center strategy, further expanding its growth ceiling. The growth rate of existing stores is anticipated to stabilize and improve [2]. - The company has opened 4,711 stores as of Q3 2023, with a significant increase in the proportion of stores outside Yunnan, rising from 18% in 2014 to 36% by Q3 2023, indicating potential for further expansion [2][27]. - The report forecasts EPS for 2023-2025 to be 3.15, 3.73, and 4.44 CNY, respectively, with a target price of 60.19 CNY, corresponding to a PE of 16X for 2024 [2][3]. Summary by Sections 1. Earnings Forecast and Valuation - The company’s revenue is projected to reach 92.29 billion CNY in 2023, 112.29 billion CNY in 2024, and 136.35 billion CNY in 2025, with year-on-year growth rates of 23%, 22%, and 21% respectively [13][14]. - The net profit attributable to the parent company is expected to be 4.05 billion CNY in 2023, 4.80 billion CNY in 2024, and 5.72 billion CNY in 2025, with growth rates of 12%, 18%, and 19% respectively [13][14]. 2. Rapid Expansion of Chain Pharmacies - The company is in a phase of rapid expansion, moving from Yunnan to other provinces, with a focus on establishing a dual-center strategy in Southwest and Hebei regions [28][27]. - The acquisition of Tangren has facilitated entry into new markets, enhancing market share [27]. 3. Industry Concentration and Same-Store Growth - The concentration of the retail pharmacy industry is increasing, with the company positioned to benefit from this trend [2]. - The same-store sales growth is expected to stabilize, benefiting from the gradual recovery of household inventories and the integration of new stores [2][40]. 4. Diversification and Sustainable Growth - The company is diversifying its business model, including beauty products and online services, which are expected to attract younger customers and differentiate it from competitors [2]. - The report highlights the importance of professional membership services and chronic disease management in enhancing customer loyalty [2]. 5. Financial Metrics - The company’s revenue for 2021 was 5,235 million CNY, increasing to 7,514 million CNY in 2022, with a projected revenue of 9,229 million CNY in 2023, reflecting a growth rate of 23% [6]. - The operating profit margin is projected to decline slightly from 7.6% in 2021 to 5.9% in 2025, while the net asset return rate is expected to improve from 14.1% in 2022 to 15.5% in 2025 [6].

证券代码：605266 证券简称：健之佳 公告编号：2024-010 健之佳医药连锁集团股份有限公司 关于持股 5%以上股东减持股份结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 股东的基本情况 公司于 2023 年 8 月 10 日公告了《关于持股 5%以上股东减持股份计划公告》 （公告编号：2023-055），股东王雁萍女士拟通过集中竞价、大宗交易方式减持 其所持股份不超过 800,000 股，不超过当时总股本的 0.6206%，减持价格按照市 场价格确定。 减持计划的实施结果情况 截至本公告披露日，本次减持计划披露的减持时间区间届满，在本次减持计 划披露的减持时间区间内，股东王雁萍女士通过竞价交易系统合计减持 2,31,970 股，占公司目前总股本的 0.1800%。 | 股东名称 | 股东身份 | 持股数量（股） | 持股比例 | 当前持股股份来源 | | | --- | --- | --- | --- | --- | --- | | 王雁萍 | 5%以上非第 | 13,118,06 ...

证券代码：605266 证券简称：健之佳 公告编号：2024-009 健之佳医药连锁集团股份有限公司 关于公司实际控制人部分股份质押及解除质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: 截止本公告日，健之佳医药连锁集团股份有限公司（以下简称"公司"） 实际控制人蓝波先生持有公司股份 17,977,465 股，占公司股份总数的 13.95%， 本次股份质押及解除质押后，蓝波先生累计质押公司股份 7,980,000 股，占其持 股总数的 44.39%，占公司总股本的 6.19%。 截至本公告日，公司实际控制人蓝波先生及其一致行动人合计持有公司 股份 52,305,043 股，占公司股份总数的 40.59%。本次质押及解除质押后，实际 控制人蓝波先生及其一致行动人累计质押股份 19,495,249 股，占其合计持股总 数的 37.27%,占公司总股本的 15.13%。 公司于近日获悉蓝波先生将其所持有的公司部分股份质押，并将部分股份解 除质押，具体情况如下: 一、本次股份质押基本情况 2、公司控股股东为深 ...

证券代码：605266 证券简称：健之佳 公告编号：2024-008 健之佳医药连锁集团股份有限公司 关于全资子公司收购四川德仁堂药业连锁有限公司 相关资产的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 健之佳医药连锁集团股份有限公司（简称"公司"）的全资子公司四川健之佳连 锁药房有限公司（简称"四川健之佳"）与交易对手四川德仁堂药业连锁有限公 司（以下简称"德仁堂"）签订《药店资产收购协议》，拟以 4,560 万元收购德仁 堂 69 家药店（以下简称"标的门店"）的门店资产及其经营权益（以下简称"目 标资产"）。通过收购目标资产，四川健之佳进一步强化在四川成都市的密集布 点，并进入新的区域，实现快速布点、获得市场份额，缩短投资回收期等目的。 特别风险提示： 1、本次交易为对门店资产及其经营权益的收购，未签署业绩对赌协议。 2、本次收购的合并成本大于可辨认净资产公允价值的差额将确认为商誉，本 次交易前，公司商誉为 240,864 万元，本次收购预计形成商誉不超过 4,560 万元， 收购完成后公司商誉预 ...